Repligen to Present at Baird’s 2017 Global Healthcare Conference
August 30 2017 - 3:20PM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that
management will present at Baird’s 2017 Healthcare Conference in
New York on Wednesday, September 6, at 9:05 a.m. EDT.
A live webcast of the presentation will be
accessible through the Investor Events section of the Company’s
website, and will be available for replay for a limited period of
time following the conference event.
About Repligen
CorporationRepligen Corporation (NASDAQ:RGEN) is a global
bioprocessing company that develops and commercializes highly
innovative products that deliver cost and process efficiencies to
biological drug manufacturers worldwide. Our portfolio includes
protein products (Protein A affinity ligands, cell culture growth
factors), chromatography products (OPUS® pre-packed columns,
chromatography resins, ELISA kits) and filtration products
(including XCell™ ATF systems, TangenX™ Sius™ flat sheet TFF
cassettes and hardware, and Spectrum KrosFlo™ hollow fiber TFF
cartridges and systems). The Protein A ligands and growth factors
that we produce are key components of affinity resins and cell
culture media, respectively. Protein A affinity resins are the
industry standard for downstream purification of monoclonal
antibody-based therapeutics. Growth factors are used in upstream
processes to accelerate cell growth and productivity. Our line of
OPUS® chromatography columns, used in downstream processes for
bench- through clinical-scale purification, are uniquely
customizable to our customers’ choice of resin and packed bed
height. Our innovative XCell™ ATF systems, available in stainless
steel and single-use configurations, continuously eliminate waste
from a bioreactor to concentrate cells and significantly increase
productivity in upstream processes. Single-use Sius™ TFF cassettes
and hardware are used for biologic drug concentration in downstream
filtration processes. Spectrum KrosFlo™ TFF cartridges and systems
are used in both upstream and downstream processes. Repligen’s
corporate headquarters are in Waltham, MA (USA), with additional
administrative and manufacturing operations in Shrewsbury, MA,
Rancho Dominguez, CA, Lund, Sweden and Weingarten, Germany.
This press release may contain forward-looking
statements within the meaning of the federal securities laws.
Investors are cautioned that statements in this press release which
are not strictly historical statements including, without
limitation, statements identified by words like “believe,”
“expect,” “may,” “will,” “should,” “seek,” or “could” and similar
expressions, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including risks discussed from time to time
in our filings with the Securities and Exchange Commission. We
expressly disclaim any responsibility to update any forward-looking
statements, except as required by law.
Repligen Contact:
Sondra S. Newman
Senior Director Investor Relations
(781) 419-1881
investors@repligen.com
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Repligen (NASDAQ:RGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024